Navigation Links
ConforMIS Completes Executive Team With Addition of CFO
Date:5/5/2008

BURLINGTON, Mass., May 5 /PRNewswire/ -- ConforMIS, Inc., a privately held company that develops and commercializes minimally invasive medical devices for the treatment of osteoarthritis and joint damage, today announced the appointment of Ms. Judith Huber to Chief Financial Officer. The addition fully rounds out the executive team, which includes recently named Chairman Philipp Lang, MD, as Chief Executive Officer and Phil Licari as Chief Operating Officer.

Ms. Huber brings more than 20 years of financial experience, predominately in the medical device industry, to ConforMIS. Most recently, Ms. Huber served as Vice President and Controller at NxStage Medical where she was instrumental in building the financial and administrative infrastructure that led to the company's initial public offering, secondary financing and acquisition of Medisystems Corporation.

"We are extremely pleased to welcome Judy as the final member of the ConforMIS executive team," said Chairman and CEO Philipp Lang, MD. "Judy joins ConforMIS at an exciting time in our company's history as we've seen demand across the globe for our line of patient-specific implants increase substantially. Her experience in building financial infrastructure to support growth on both the operations and commercialization fronts will play a key role as we head into the second half of 2008 and beyond."

Prior to joining NxStage Medical, Ms. Huber spent more than nine years in various financial positions with C. R. Bard and AVE/Medtronic. She supported multiple divisions focused on improving the economic efficiencies of their manufacturing operations.

"I'm looking forward to working with an accomplished team of executives at such an important and exciting time in ConforMIS' growth," said Ms. Huber. "Delivering on the opportunity to build a robust financial capability for ConforMIS will enable the company to continue on the path to becoming a major player in the orthopedic market."

Ms. Huber earned a B.S. in Accounting from the State University of New York at Geneseo and an M.B.A. from the Babson College. She is also a Certified Management Accountant.

About ConforMIS, Inc.

ConforMIS, Inc. is a privately held company incorporated in 2004 that develops and commercializes medical devices for the treatment of osteoarthritis and joint damages. The Company's novel and scaleable 'image-to-implant' process is comprised of two related technology platforms. iFit(TM) Technology enables the creation of conforming, patient-specific implants that are precisely sized and shaped to match the 3D topography of the patient's bone surfaces. The iJig(TM) Instrumentation enables the creation of novel, disposable cutting and placement guides that simplify and improve the surgical process.

Both platforms are supported by proprietary, intellectual property consisting of more than 120 issued patents or pending patent applications that span imaging software, image processing, implant design, surgical techniques and instrumentation.

To date, ConforMIS has developed a comprehensive line of minimally traumatic, bone and cartilage-preserving knee implants and instrumentation designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery. Each device has been cleared by the U.S. Food and Drug Administration for marketing in the U.S.

ConforMIS, Inc. Contact:

Jong Lee

Senior Vice President, Marketing

781-345-9107

Media Contact:

Sally Bain

Racepoint Group

781-487-4647

sbain@racepointgroup.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE ConforMIS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: